IBT Stock Overview
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IBEX Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.44 |
| 52 Week High | CA$1.45 |
| 52 Week Low | CA$0.75 |
| Beta | -0.045 |
| 1 Month Change | 1.41% |
| 3 Month Change | 30.91% |
| 1 Year Change | 73.49% |
| 3 Year Change | 300.00% |
| 5 Year Change | 772.73% |
| Change since IPO | -66.12% |
Recent News & Updates
Recent updates
The Market Lifts IBEX Technologies Inc. (CVE:IBT) Shares 27% But It Can Do More
Feb 13
IBEX Technologies' (CVE:IBT) Earnings Might Not Be As Promising As They Seem
Dec 22Market Might Still Lack Some Conviction On IBEX Technologies Inc. (CVE:IBT) Even After 28% Share Price Boost
Dec 19Calculating The Fair Value Of IBEX Technologies Inc. (CVE:IBT)
Oct 05A Look At The Fair Value Of IBEX Technologies Inc. (CVE:IBT)
May 22Shareholders May Be More Conservative With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation For Now
Jan 19We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation
Feb 10Investors Shouldn't Be Too Comfortable With IBEX Technologies' (CVE:IBT) Robust Earnings
Mar 25IBEX Technologies Inc.'s (CVE:IBT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 22How Should Investors React To IBEX Technologies' (CVE:IBT) CEO Pay?
Dec 29Shareholder Returns
| IBT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | -3.0% |
| 1Y | 73.5% | -33.7% | 3.2% |
Return vs Industry: IBT exceeded the Canadian Biotechs industry which returned -29.5% over the past year.
Return vs Market: IBT exceeded the Canadian Market which returned 7.8% over the past year.
Price Volatility
| IBT volatility | |
|---|---|
| IBT Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 14.0% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: IBT's share price has been volatile over the past 3 months.
Volatility Over Time: IBT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Paul Baehr | www.ibex.ca |
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.
IBEX Technologies Inc. Fundamentals Summary
| IBT fundamental statistics | |
|---|---|
| Market cap | CA$35.30m |
| Earnings (TTM) | CA$3.98m |
| Revenue (TTM) | CA$8.00m |
8.9x
P/E Ratio4.4x
P/S RatioIs IBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT income statement (TTM) | |
|---|---|
| Revenue | CA$8.00m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | CA$5.77m |
| Other Expenses | CA$1.79m |
| Earnings | CA$3.98m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 72.11% |
| Net Profit Margin | 49.70% |
| Debt/Equity Ratio | 0% |
How did IBT perform over the long term?
See historical performance and comparison